We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Risk Marker Found for Late-Life Depression

By LabMedica International staff writers
Posted on 22 Nov 2015
The epsilon 4 (ε4) allele of the apolipoprotein gene (APOE) has been associated with atherosclerosis as well as cardiovascular and cerebrovascular disease but it is less clear whether there is also an association with geriatric depression.

Individuals who carry the APOE ε4, one of the most powerful predictors in neuropsychiatry, are at increased risk for developing Alzheimer's disease, early age of Alzheimer's disease onset, and more rapid progression of Alzheimer's disease symptoms. More...


Scientists at the University of Gothenburg (Sweden) and their international colleagues enrolled 839 women and men with an age range, 70 to 92 years and a mean age, 73.8 years. The enrollees were free from dementia and depression that underwent neuropsychiatric and neuropsychological examinations and genotyping of the APOE ε4 allele. Follow-up evaluations were conducted in 2005 and 2009.The association between APOE ε4 allele and five year incidence of depression was examined, while avoiding possible confounding effects of clinical or preclinical dementia by excluding participants who had dementia at study entry, subsequently developed dementia during the nine year follow-up period.

Blood samples were collected, and APOE (gene map locus 19q13.2) genotyping was performed by minisequencing and was successful for 100% of the consenting participants. Genotypes were obtained for the two single nucleotide polymorphisms (rs7412 and rs429358) that are used to define unambiguously ε2, ε3, and ε4 alleles. Dementia was diagnosed by geriatric psychiatrists based on symptoms rated during the neuropsychiatric examinations and information from the close informant interviews.

In 2000, major depression was diagnosed in 32 participants, and minor depression was diagnosed in 94 participants. No associations could be observed at baseline between the APOE ε4 allele and minor depression. No interactions by sex regarding the association between depression and APOE ε4 could be seen and the presence of the APOE ε4 allele was not related to 5-year or 9-year mortality. However between 2000 and 2009, 103 individuals developed dementia; 50 new cases based on the 2005 examination, 53 new cases based on the 2009 examination. In a multiple logistic regression model (including age and sex), presence of the APOE ε4 allele was associated with dementia development during 2001to 2009.

Silke Kern, MD, PhD, the lead author of the study, said, “In our study, the presence of the APOE ε4 predicted future depression, even after excluding individuals who later developed dementia. It was also related to dementia. APOE ε4 might be a marker for identifying older persons at risk to develop depression or dementia, which could be important for prevention and early detection of these common disorders.” The study was published on November 15, 2015, in the journal Biological Psychiatry.

Related Links:

University of Gothenburg



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.